ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy

Abstract Spinal muscular atrophy (SMA) is one of the leading genetic diseases of children and infants. SMA is caused by deletions or mutations of Survival Motor Neuron 1 (SMN1) gene. SMN2, a nearly identical copy of SMN1, cannot compensate for the loss of SMN1 due to predominant skipping of exon 7. While various regulatory elements that modulate SMN2 exon 7 splicing have been proposed, intronic splicing silencer N1 (ISS-N1) has emerged as the most promising target thus far for antisense oligonucleotide-mediated splicing correction in SMA. Upon procuring exclusive license from the University of Massachussets Medical School in 2010, Ionis Pharmaceuticals (formerly ISIS Pharamaceuticals) began clinical development of Spinraza™ (synonyms: Nusinersen, IONIS-SMNRX, ISIS-SMNRX), an antisense drug based on ISS-N1 target. Spinraza™ showed very promising results at all steps of the clinical development and was approved by US Food and Drug Administration (FDA) on December 23, 2016. Spinraza™ is the first FDA-approved treatment for SMA and the first antisense drug to restore expression of a fully functional protein via splicing correction. The success of Spinraza™ underscores the potential of intronic sequences as promising therapeutic targets and sets the stage for further improvement of antisense drugs based on advanced oligonucleotide chemistries and delivery protocols.

• Publication year

  2017

• Venue

  Translational Neuroscience

• Publication date

  2017-01-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1515/tnsci-2017-0001PMID 28400976PMCID 5382937
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diverse role of survival motor neuron protein.

  2017cited by this paper
• The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.

  2017cited by this paper
• Survival of motor neurone protein is required for normal postnatal development of the spleen

  2017cited by this paper
• Chapter 5 – Transcriptional and Splicing Regulation of Spinal Muscular Atrophy Genes

  2017cited by this paper
• Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy

  2016cited by this paper
• Evolution of the intrinsic electronic phase separation in La0.6Er0.1Sr0.3MnO3 perovskite

  2016cited by this paper
• Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy

  2016cited by this paper
• Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy

  2016cited by this paper
• Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment

  2016cited by this paper
• Survival Motor Neuron (SMN) protein is required for normal mouse liver development

  2016cited by this paper
• A novel human-specific splice isoform alters the critical C-terminus of Survival Motor Neuron protein

  2016cited by this paper
• Temperature dependent fracture properties of shape memory alloys: novel findings and a comprehensive model

  2016cited by this paper
• Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia

  2016cited by this paper
• Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.

  2016cited by this paper
• Oxidative Stress Triggers Body-Wide Skipping of Multiple Exons of the Spinal Muscular Atrophy Gene

  2016cited by this paper
• Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy

  2016cited by this paper
• Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response.

  2015cited by this paper
• Splicing regulation in spinal muscular atrophy by an RNA structure formed by long‐distance interactions

  2015cited by this paper
• Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

  2015cited by this paper
• SMN deficiency disrupts gastrointestinal and enteric nervous system function in mice.

  2015cited by this paper
• SMN deficiency disrupts gastrointestinal and enteric nervous system function in mice.

  2015cited by this paper
• Advances in therapeutic development for spinal muscular atrophy.

  2014cited by this paper
• Spinal Muscular Atrophy: Journeying From Bench to Bedside

  2014cited by this paper
• A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy

  2014cited by this paper
• Antisense methods to modulate pre-mRNA splicing.

  2014cited by this paper
• Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2 gene.

  2014cited by this paper
• Dual Masking of Specific Negative Splicing Regulatory Elements Resulted in Maximal Exon 7 Inclusion of SMN2 Gene.

  2014cited by this paper
• Faculty Opinions recommendation of Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.

  2014cited by this paper
• Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy

  2013cited by this paper
• Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy

  2013cited by this paper
• Antisense oligonucleotide mediated therapy of spinal muscular atrophy

  2013cited by this paper
• Improved Antisense Oligonucleotide Design to Suppress Aberrant SMN2 Gene Transcript Processing: Towards a Treatment for Spinal Muscular Atrophy

  2013cited by this paper
• Dengue Virus Type 3 Adaptive Changes during Epidemics in São Jose de Rio Preto, Brazil, 2006–2007

  2013cited by this paper
• Shift from Extracellular Signal-Regulated Kinase to AKT/cAMP Response Element-Binding Protein Pathway Increases Survival-Motor-Neuron Expression in Spinal-Muscular-Atrophy-Like Mice and Patient Cells

  2013cited by this paper
• Spinal muscular atrophy: an update on therapeutic progress.

  2013cited by this paper
• An intronic structure enabled by a long-distance interaction serves as a novel target for splicing correction in spinal muscular atrophy

  2013cited by this paper
• A Novel Morpholino Oligomer Targeting ISS-N1 Improves Rescue of Severe Spinal Muscular Atrophy Transgenic Mice

  2013cited by this paper
• A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.

  2012cited by this paper
• A Multi-Exon-Skipping Detection Assay Reveals Surprising Diversity of Splice Isoforms of Spinal Muscular Atrophy Genes

  2012cited by this paper
• Ubiquitin-specific Protease 9x Deubiquitinates and Stabilizes the Spinal Muscular Atrophy Protein-Survival Motor Neuron*

  2012cited by this paper
• Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy.

  2012cited by this paper
• Functional Analysis of Large Exonic Sequences Through Iterative In Vivo Selection

  2012cited by this paper
• Identification of Splicing cis‐Elements Through an Ultra‐Refined Antisense Microwalk

  2012cited by this paper
• Design principles for bifunctional targeted oligonucleotide enhancers of splicing

  2011cited by this paper
• Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model

  2011cited by this paper
• Alternative splicing in spinal muscular atrophy underscores the role of an intron definition model

  2011cited by this paper
• Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy

  2011cited by this paper
• A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity.

  2010cited by this paper
• Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.

  2010cited by this paper
• Cardiac defects contribute to the pathology of spinal muscular atrophy models.

  2010cited by this paper
• Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice.

  2010cited by this paper
• Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) regulates the level of SMN expression through ubiquitination in primary spinal muscular atrophy fibroblasts.

  2010cited by this paper
• An antisense microwalk reveals critical role of an intronic position linked to a unique long-distance interaction in pre-mRNA splicing.

  2010cited by this paper
• TIA1 Prevents Skipping of a Critical Exon Associated with Spinal Muscular Atrophy

  2010cited by this paper
• Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy.

  2009cited by this paper
• Oligonucleotide-Mediated Survival of Motor Neuron Protein Expression in CNS Improves Phenotype in a Mouse Model of Spinal Muscular Atrophy

  2009cited by this paper
• A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy

  2009cited by this paper
• Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo.

  2009cited by this paper
• Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation.

  2009cited by this paper
• Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice.

  2008cited by this paper
• Spinal muscular atrophy.

  2008cited by this paper
• Unfolding the mystery of alternative splicing through a unique method of in vivo selection.

  2007cited by this paper
• Axonal-SMN (a-SMN), a protein isoform of the survival motor neuron gene, is specifically involved in axonogenesis

  2007cited by this paper
• Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes

  2006cited by this paper
• Defective splicing, disease and therapy: searching for master checkpoints in exon definition

  2006cited by this paper
• Splicing of a Critical Exon of Human Survival Motor Neuron Is Regulated by a Unique Silencer Element Located in the Last Intron

  2006cited by this paper
• In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes.

  2004cited by this paper
• The regulation and regulatory activities of alternative splicing of the SMN gene.

  2004cited by this paper
• An extended inhibitory context causes skipping of exon 7 of SMN2 in spinal muscular atrophy.

  2004cited by this paper
• Correction of disease-associated exon skipping by synthetic exon-specific activators

  2003cited by this paper
• A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy

  2003cited by this paper
• Identification of a Cis-acting Element for the Regulation ofSMN Exon 7 Splicing*

  2002cited by this paper
• Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1

  2002cited by this paper
• An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)

  2000cited by this paper
• A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy.

  1999cited by this paper
• A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2.

  1999cited by this paper
• Identification and characterization of a spinal muscular atrophy-determining gene

  1995cited by this paper

• Demystifying Gene-Based Therapies in Pediatric Health Care

  2026cites this paper
• Selection of specific and efficient siRNAs in new cellular model for Hutchinson-Gilford progeria syndrome therapy

  2025cites this paper
• A shape-based functional index for objective assessment of pediatric motor function

  2025cites this paper
• Single Antisense Oligonucleotides Correct Diverse Splicing Mutations in Hotspot Exons

  2025cites this paper
• Short Review on Currently Used Sample Preparation and Determination Methods of Risdiplam.

  2025cites this paper
• A novel splice site variant in DEGS1 leads to aberrant splicing and loss of DEGS1 enzyme activity, a VUS resolved

  2025cites this paper
• Gene Therapy Drugs Based on Synthetic Oligonucleotides

  2025cites this paper
• Fluoroscopic guidance for intrathecal delivery of nusinersen in pediatric patients with spinal muscular atrophy and complex spines.

  2025cites this paper
• Retinal degeneration in spinocerebellar ataxia type 7: an overview of the current knowledge.

  2025cites this paper
• The evolution and application of RNA-focused small molecule libraries

  2025cites this paper
• Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group

  2025cites this paper
• Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy

  2025cites this paper
• Pre-mRNA Splicing Modulation by Antisense Oligonucleotides.

  2025cites this paper
• MCARSMA: A Multi-Level Cross-Modal Attention Fusion Framework for Accurate RNA–Small Molecule Affinity Prediction

  2025cites this paper
• Comprehensive Overview of Computational Tools for Alternative Splicing Analysis

  2025cites this paper
• Generation of tumor neoantigens by RNA splicing perturbation.

  2024cites this paper
• Circadian rhythm in neurodegenerative disease: the role of RNA modifications and potential application of RNA-based therapeutics

  2024cites this paper
• Current status of nucleic acid therapy and its new progress in cancer treatment.

  2024cites this paper
• Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges

  2024cites this paper
• Rational Design Problematics of Peptide Nucleic Acids as SARS-CoV-2 Inhibitors

  2024cites this paper
• Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3.

  2024cites this paper
• Advances in RNA therapeutics for modulation of 'undruggable' targets.

  2024cites this paper
• Oligonucleotide therapeutics and their chemical modification strategies for clinical applications

  2024cites this paper
• RNA Therapeutics for the Cardiovascular System

  2024cites this paper
• Separation and purification of short-, medium-, and long-stranded RNAs by RP-HPLC using different mobile phases and C18 columns with various pore sizes.

  2024cites this paper
• Spinal adhesive arachnoiditis in an adult patient with spinal muscular atrophy type 3 treated with intrathecal therapy

  2024cites this paper
• Effect of nusinersen on pulmonary function in children with spinal muscular atrophy in the plateau region: A pilot study

  2024cites this paper
• The spinal muscular atrophy gene product regulates actin dynamics

  2024cites this paper
• Developing Therapeutic Splice-Correcting Antisense Oligomers for Adult-Onset Pompe Disease with c.-32-13T>G Mutation.

  2023cites this paper
• Alternative splicing in neurodegenerative disease and the promise of RNA therapies

  2023cites this paper
• Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies

  2023cites this paper
• Targeted ASO-mediated Atp1a2 knockdown in astrocytes reduces SOD1 aggregation and accelerates disease onset in mutant SOD1 mice

  2023cites this paper
• Base editing rescue of spinal muscular atrophy in cells and in mice

  2023cites this paper
• Unilateral interlaminar fenestration on the convex side provides a reliable access for intrathecal administration of nusinersen in spinal muscular atrophy: a retrospective study

  2023cites this paper
• Synthesis and chemical transformations of glycol nucleic acid (GNA) nucleosides.

  2023cites this paper
• The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study

  2023cites this paper
• Molecular Biomarkers for the Diagnosis, Prognosis, and Pharmacodynamics of Spinal Muscular Atrophy

  2023cites this paper
• Feasibility analysis of intrathecal administration strategy of nusinersen based on Cobb angle in children with spinal muscular atrophy.

  2023cites this paper
• The phospho-landscape of the survival of motoneuron protein (SMN) protein: relevance for spinal muscular atrophy (SMA)

  2022cites this paper
• Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1–3 patients treated with nusinersen

  2022cites this paper
• Bridging the Gap With Clinical Pharmacology in Innovative Rare Disease Treatment Modalities: Targeting DNA to RNA to Protein

  2022cites this paper
• Utilization and Potential of RNA-Based Therapies in Cardiovascular Disease

  2022cites this paper
• Shape Analysis for Pediatric Upper Body Motor Function Assessment

  2022cites this paper
• Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition

  2022cites this paper
• Developing antisense oligonucleotides for a TECPR2 mutation-induced, ultra-rare neurological disorder using patient-derived cellular models

  2022cites this paper
• Gene therapy clinical trials, where do we go? An overview.

  2022cites this paper
• The Progress and Promise of RNA Medicine—An Arsenal of Targeted Treatments

  2022cites this paper
• High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed SMN2 Splicing in Patient Fibroblasts

  2022cites this paper
• Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy

  2022cites this paper
• Usefulness of functional splicing analysis to confirm precise disease pathogenesis in Diamond-Blackfan anemia caused by intronic variants in RPS19

  2021cites this paper
• Parents’ perspectives on nusinersen treatment for children with spinal muscular atrophy

  2021cites this paper
• High Concentration of an ISS-N1-Targeting Antisense Oligonucleotide Causes Massive Perturbation of the Transcriptome

  2021cites this paper
• Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

  2021cites this paper
• Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1–3

  2021cites this paper
• Antisense oligonucleotides targeting the SMN2 promoter region enhance SMN2 expression in spinal muscular atrophy cell lines and mouse model.

  2021cites this paper
• The Impact of Upcoming Treatments in Huntington’s Disease: Resource Capacity Limitations and Access to Care Implications

  2021cites this paper
• Alpha-synuclein spreading mechanisms in Parkinson's disease: The role of membrane receptors

  2021cites this paper
• Single Nucleotide Resolution RNA–Protein Cross-Linking Mass Spectrometry: A Simple Extension of the CLIR-MS Workflow

  2021cites this paper
• Alternative strategies in cardiac preclinical research and new clinical trial formats

  2021cites this paper
• RNA Targeting in Inherited Neuromuscular Disorders: Novel Therapeutic Strategies to Counteract Mis-Splicing

  2021cites this paper
• Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations

  2021cites this paper
• Prenatal transplantation of human amniotic fluid stem cell could improve clinical outcome of type III spinal muscular atrophy in mice

  2020cites this paper
• Small molecule targeting of RNA structures in neurological disorders

  2020cites this paper
• Targeting the Oncogenic Long Non-coding RNA SLNCR1 by Blocking Its Sequence-Specific Binding to the Androgen Receptor.

  2020cites this paper
• R-Roscovitine Improves Motoneuron Function in Mouse Models for Spinal Muscular Atrophy

  2020cites this paper
• Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model

  2020cites this paper
• [Gene-based therapies of spinal muscular atrophy: a piece of history of medicine].

  2020cites this paper
• Splice modulating antisense oligonucleotides restore some acid-alpha-glucosidase activity in cells derived from patients with late-onset Pompe disease

  2020cites this paper
• RNA-Targeted Therapies and High-Throughput Screening Methods

  2020cites this paper
• Design, Optimization, and Study of Small Molecules That Target Tau Pre-mRNA and Affect Splicing.

  2020cites this paper
• A survey of transcripts generated by spinal muscular atrophy genes.

  2020cites this paper
• Generating ventral spinal organoids from human induced pluripotent stem cells.

  2020cites this paper
• Antisense Antibacterial Compounds.

  2020cites this paper
• The Role of Alternative RNA Splicing in the Regulation of hTERT, Telomerase, and Telomeres: Implications for Cancer Therapeutics

  2020cites this paper
• RNA in spinal muscular atrophy: therapeutic implications of targeting

  2020cites this paper
• Characteristics of circular RNAs generated by human Survival Motor Neuron genes.

  2020cites this paper
• Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents

  2020cites this paper
• Discovery and evolution of RNA and XNA reverse transcriptase function and fidelity

  2020cites this paper
• Emerging Contribution of PancRNAs in Cancer

  2020cites this paper
• Intrinsic Regulatory Role of RNA Structural Arrangement in Alternative Splicing Control

  2020cites this paper
• Gene Therapy in the Management of Parkinson's Disease: Potential of GDNF as a Promising Therapeutic Strategy.

  2020cites this paper
• Gene therapy: An updated overview on the promising success stories.

  2020cites this paper
• Intrathecal Access Through Suboccipital Port in Patients With Spinal Muscular Atrophy and Complex Spines: Case Series and Technical Note

  2020cites this paper
• RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges

  2020influential citation
• Non-Viral Targeted Nucleic Acid Delivery: Apply Sequences for Optimization

  2020cites this paper
• Epigenetics of neuromuscular disorders.

  2020cites this paper
• Antisense oligonucleotide drugs for neurological and neuromuscular disease

  2020cites this paper
• Pharmacokinetics and Proceedings in Clinical Application of Nucleic Acid Therapeutics.

  2020cites this paper
• Nucleic Acid-Based Technologies Targeting Coronaviruses

  2020cites this paper
• The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy

  2020cites this paper
• Percepção das famílias de pacientes com atrofia muscular espinhal sobre a utilização da spinraza® associada ao tratamento fisioterapêutico

  2020cites this paper
• Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules

  2020cites this paper
• Engineering precision therapies: lessons and motivations from the clinic

  2020cites this paper
• Modified internucleoside linkages for nuclease-resistant oligonucleotides

  2020cites this paper
• Newborn Screening for Spinal Muscular Atrophy in China Using DNA Mass Spectrometry

  2019cites this paper
• Developing small activating RNA as a therapeutic: current challenges and promises.

  2019cites this paper
• Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy

  2019cites this paper
• Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics

  2019cites this paper
• High-throughput screening reveals novel mutations in spinal muscular atrophy patients

  2019cites this paper
• Autophagy and Spinal Muscular Atrophy: Towards a Pathway-Centric Therapy for a Fatal Childhood Disorder

  2019cites this paper